Citation: | ZHANG Xiaojiao, ZHANG Hailong, XIANG Youqin, DING Jinsong. Dose dumping of levomilnacipran hydrochloride sustained-release capsules[J]. Journal of China Pharmaceutical University, 2022, 53(1): 60-66. DOI: 10.11665/j.issn.1000-5048.20220109 |
[1] |
.
|
[2] |
FDA. Information for healthcare professionals: hydromorphone hydrochloride extended-release capsules(marketed as Palladone)[EB/OL].
|
[3] |
Murray S,Wooltorton E. Alcohol-associated rapid release of a long-acting opioid[J]. CMAJ,2005,173(7): 756.
|
[4] |
Darke AC. Controlled-release opioids and alcohol[J]. CMAJ,2006,174(3):352.
|
[5] |
Anand O,Yu LX,Conner DP,et al. Dissolution testing for generic drugs:an FDA perspective[J]. AAPS J,2011,13(3):328-335.
|
[6] |
PMDA.Regarding concepts on bioequivalence test of production change of oral solid preparation[EB].[
|
[7] |
FDA.Levomilnacipran[EB/OL].[
|
[8] |
Hair P,Cameron F,Garnock-Jones KP. Levomilnacipran extended release:first global approval[J]. Drugs,2013,73(14):1639-1645.
|
[9] |
He S,Yang XM,Li HF. New antidepressant:levomilnacipran[J].Chin J New Drugs Clin Med(中国新药与临床杂志),2015,34(6):418-422.
|
[10] |
Surana R,Divi M,Chhettry A. Stable dosage forms of levomilnacipran:
US8481598[P]. |
[11] |
Narisawa S,Yoshino H,Hirakawa Y,et al. Porosity-controlled ethylcellulose film coating. I. formation of porous ethylcellulose film in the casting process and factors affecting film-density[J]. Chem Pharm Bull,1993,41(2):329-334.
|